VentiMate™
Real-time, wearable relief for asthma and EIB — when it matters most.
Breathe Easier, Live Freer with VentiMate™
Asthma: A Widespread Challenge
Asthma is one of the most prevalent chronic disorders worldwide, affecting over 336 million people globally, including 25 million in the United States. A common and often under-recognised complication is exercise-induced bronchoconstriction (EIB) — the narrowing of airways during or after physical activity.
EIB affects up to 90% of people with asthma, and up to 50% of athletes, particularly those engaged in high-intensity or endurance sports. While reliever inhalers remain the first-line treatment, chronic reliance can lead to long-term risks, reduced medication effectiveness, and worsened outcomes. The easy access to over-the-counter relievers has contributed to inappropriate use and exacerbation of asthma symptoms — revealing a critical gap in current management strategies.
Our Vision
We aim to empower the millions affected by asthma and EIB with VentiMate™ — a wearable, non-invasive device that delivers real-time relief when it’s needed most. Operating in a closed-loop system, VentiMate detects early signs of bronchoconstriction and delivers targeted stimulation, extending the window before medication is required and restoring confidence in appropriate inhaler use.
We envision a world where individuals are no longer limited by respiratory symptoms — where technology bridges the gap between symptom onset and medical intervention, helping people breathe easier, move freely, and live with greater control over their condition.
Our Story
VentiMate™ is currently under development at the University of Otago, New Zealand.
(PCT filed; priority date 07/11/2023)
We are looking for partners/investors to join our mission. Join us to help patients with asthma enjoy greater freedom, have reduced hospital visits, and enhanced quality of life.